Literature DB >> 16637789

Adverse drug reactions in United States hospitals.

C A Bond1, Cynthia L Raehl.   

Abstract

Adverse drug reactions (ADRs) were examined in 8,208,960 hospitalized Medicare patients in 1998. A database was constructed from the 1998 MedPAR database. The study population was composed of 141,398 Medicare patients who experienced an ADR (rate of 1.73%). The most common drug classes associated with ADRs were cardiotonic glycosides, adrenal corticosteroids, antineoplastic agents, anticoagulants, and analgesics. The most common associated diagnoses were hypertension, congestive heart failure, atrial fibrillation, volume depletion disorders, and atherosclerotic heart disease. In patients who experienced an ADR, death rates were 19.18% higher with 1971 excess deaths (odds ratio 1.208, 95% confidence interval 1.184-1.234), and length of hospital stay was 8.25% higher with 77,769 excess patient-days (Mann-Whitney U test [U]=200078720610, p<0.0001). Charges for patients with an ADR were increased as follows: total Medicare 19.86% (339,496,598 US dollars, U=200,089,611,739, p<0.0001), drugs 9.15% (24,744,650 US dollars, U=208,719,928,502, p<0.0001), and laboratory charges 2.82% (6,221,512 US dollars, U=195,143,498,450, p<0.0001). We developed a list of high-risk diagnoses and drug classes to help pharmacists target patients who are more likely to experience ADRs. This is the first study to evaluate the ADRs in a large population of hospitalized Medicare patients. These findings will enable pharmacists to develop better management programs for ADRs.

Entities:  

Mesh:

Year:  2006        PMID: 16637789     DOI: 10.1592/phco.26.5.601

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  28 in total

1.  Adverse drug reactions in internal medicine units and associated risk factors.

Authors:  Juan Francisco Sánchez Muñoz-Torrero; Paloma Barquilla; Raul Velasco; Maria del Carmen Fernández Capitan; Nazaret Pacheco; Lucia Vicente; Jose Luis Chicón; Sara Trejo; Jose Zamorano; Alicia Lorenzo Hernandez
Journal:  Eur J Clin Pharmacol       Date:  2010-08-06       Impact factor: 2.953

2.  Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan.

Authors:  Yuichi Tasaka; Daiki Yasunaga; Mamoru Tanaka; Akihiro Tanaka; Takashige Asakawa; Ikuo Horio; Yoshiro Miyauchi; Hiroaki Araki
Journal:  Int J Clin Pharm       Date:  2016-01-08

3.  Development and evaluation of a required patient safety course.

Authors:  Sana R Sukkari; Larry D Sasich; Donald A Tuttle; Asim M Abu-Baker; Hannah Howell
Journal:  Am J Pharm Educ       Date:  2008-06-15       Impact factor: 2.047

Review 4.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

5.  Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.

Authors:  O Alagoz; D Durham; K Kasirajan
Journal:  Pharmacogenomics J       Date:  2015-05-19       Impact factor: 3.550

6.  Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.

Authors:  Philip N Okafor; Francis A Farraye; Adetoro T Okafor; Daniel O Erim
Journal:  Dig Dis Sci       Date:  2015-07-16       Impact factor: 3.199

7.  Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis.

Authors:  Irma Convertino; Stefano Salvadori; Alessandro Pecori; Maria Teresa Galiulo; Sara Ferraro; Maria Parrilli; Tiberio Corona; Giuseppe Turchetti; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

8.  Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum.

Authors:  Edith A Nutescu; Ann K Wittkowsky; Allison Burnett; Geno J Merli; Jack E Ansell; David A Garcia
Journal:  Ann Pharmacother       Date:  2013-04-12       Impact factor: 3.154

Review 9.  Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors.

Authors:  Mulugeta Tarekegn Angamo; Leanne Chalmers; Colin M Curtain; Luke R E Bereznicki
Journal:  Drug Saf       Date:  2016-09       Impact factor: 5.606

10.  Adverse drug reactions and deliberate self-poisoning as cause of admission to the intensive care unit: a 1-year prospective observational cohort study.

Authors:  Lukas Schwake; Ines Wollenschläger; Wolfgang Stremmel; Jens Encke
Journal:  Intensive Care Med       Date:  2008-08-12       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.